Raia Drogasil S.A. (OTCMKTS:RADLY – Get Free Report) hit a new 52-week low on Monday. The company traded as low as $2.88 and last traded at $2.9480, with a volume of 2,068 shares changing hands. The stock had previously closed at $4.16.
Analysts Set New Price Targets
Separately, Jefferies Financial Group raised Raia Drogasil to a “buy” rating and set a $5.20 target price for the company in a research report on Sunday, October 18th. One equities research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $5.20.
Get Our Latest Research Report on Raia Drogasil
Raia Drogasil Stock Performance
Raia Drogasil (OTCMKTS:RADLY – Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $0.05 earnings per share for the quarter, hitting the consensus estimate of $0.05. The business had revenue of $2.17 billion during the quarter, compared to analysts’ expectations of $2.32 billion. On average, sell-side analysts predict that Raia Drogasil S.A. will post 0.17 EPS for the current year.
About Raia Drogasil
Raia Drogasil, now operating under the name RD Saúde, is a Brazilian healthcare and pharmacy retail company. It operates a network of pharmacies offering prescription medicines, over-the-counter drugs, vitamins, personal care products, beauty items and other health-related merchandise.
The company also provides digital purchasing and delivery services through its online channels, supporting customers with prescription fulfillment, health products and related services. Its operations include pharmacy-based healthcare initiatives designed to complement its retail business and improve access to everyday healthcare.
RD Saúde was created in 2011 through the merger of Drogasil and Droga Raia, two established Brazilian pharmacy chains.
See Also
- Five stocks we like better than Raia Drogasil
- Taiwan Semiconductor Flexes Pricing Power on AI’s Frontline
- Hidden in Plain Sight: 2 Earnings Winners Investors May Have Missed
- These 3 New ETFs Are Turning Heads—Are They Worth Buying?
- Coca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest Strength
Receive News & Ratings for Raia Drogasil Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Raia Drogasil and related companies with MarketBeat.com's FREE daily email newsletter.
